Dasatinib Monohydrate: A Targeted Therapy for Leukemia
Discover the advanced oral treatment for CML and Ph+ ALL, powered by potent tyrosine kinase inhibition.
Get a Quote & SampleProduct Core Value
Dasatinib Monohydrate
An oral Bcr-Abl tyrosine kinase inhibitor that also targets the Src family of tyrosine kinases, Dasatinib Monohydrate is a vital medication for patients battling chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its development represents a significant advancement in targeted cancer therapy, offering a more precise approach to treatment.
- Explore the intricacies of Dasatinib Monohydrate for CML treatment, understanding its mechanism against the 'Philadelphia chromosome'.
- Learn about the specific applications of Dasatinib Monohydrate for Ph+ ALL, highlighting its role in managing this aggressive leukemia.
- Investigate the pharmacological action of this potent tyrosine kinase inhibitor, focusing on its inhibition of Bcr-Abl and Src family kinases.
- Understand the potential side effects of Dasatinib Monohydrate, including bone marrow suppression and the rare risk of pulmonary arterial hypertension.
Key Advantages of Dasatinib Monohydrate
Targeted Efficacy
As a leading tyrosine kinase inhibitor, Dasatinib Monohydrate offers targeted efficacy against specific genetic mutations driving leukemia, leading to more precise treatment outcomes.
Oral Administration Convenience
The oral formulation of Dasatinib Monohydrate enhances patient convenience, potentially improving quality of life and adherence compared to intravenous treatments.
Broad Application Spectrum
Beyond its primary indications, research into Dasatinib Monohydrate continues to explore its potential uses in other cancers and conditions, showcasing its versatility as a therapeutic agent.
Key Applications
Chronic Myelogenous Leukemia (CML)
Dasatinib Monohydrate is a cornerstone therapy for CML, targeting the underlying Bcr-Abl fusion protein that drives the disease, offering improved patient outcomes.
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)
Its efficacy extends to Ph+ ALL, providing a crucial treatment option for patients with this specific subtype of leukemia.
Oncology Research & Development
Serves as a critical pharmaceutical intermediate and research compound for exploring new cancer therapies and understanding kinase inhibitor mechanisms.
Senolytic Research
Emerging research suggests potential applications in senolytic therapy, indicating a broader role in cellular health and aging research.